Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Feb 15;209(4):542-50.
doi: 10.1093/infdis/jit467. Epub 2013 Aug 27.

Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study

Francisco M Marty  1 , Choy Y Man, Charles van der Horst, Bruno Francois, Denis Garot, Rafael Mánez, Visanu Thamlikitkul, José A Lorente, Francisco Alvarez-Lerma, David Brealey, Henry H Zhao, Steve Weller, Phillip J Yates, Amanda F Peppercorn
Affiliations
Clinical Trial

Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study

Francisco M Marty et al. J Infect Dis. .

Abstract

Background: Intravenous zanamivir is a neuraminidase inhibitor suitable for treatment of hospitalized patients with severe influenza.

Methods: Patients were treated with intravenous zanamivir 600 mg twice daily, adjusted for renal impairment, for up to 10 days. Primary outcomes included adverse events (AEs), and clinical/laboratory parameters. Pharmacokinetics, viral load, and disease course were also assessed.

Results: One hundred thirty patients received intravenous zanamivir (median, 5 days; range, 1-11) a median of 4.5 days (range, 1-7) after onset of influenza; 83% required intensive care. The most common influenza type/subtype was A/H1N1pdm09 (71%). AEs and serious AEs were reported in 85% and 34% of patients, respectively; serious AEs included bacterial pulmonary infections (8%), respiratory failure (7%), sepsis or septic shock (5%), and cardiogenic shock (5%). No drug-related trends in safety parameters were identified. Protocol-defined liver events were observed in 13% of patients. The 14- and 28-day all-cause mortality rates were 13% and 17%. No fatalities were considered zanamivir related. Pharmacokinetic data showed dose adjustments for renal impairment yielded similar zanamivir exposures. Ninety-three patients, positive at baseline for influenza by quantitative polymerase chain reaction, showed a median decrease in viral load of 1.42 log10 copies/mL after 2 days of treatment.

Conclusions: Safety, pharmacokinetic and clinical outcome data support further investigation of intravenous zanamivir.

Clinical trials registration: NCT01014988.

Keywords: A/H1N1pdm09; Influenza; hospitalized; intravenous zanamivir; pandemic influenza; safety; zanamivir.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Median change from baseline influenza A or B viral load by quantitative real-time polymerase chain reaction in patients with positive baseline results; interquartile ranges are also shown.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. US Department of Health and Human Services. HHS pandemic influenza plan. 2005. http://www.flu.gov/planning-preparedness/federal/hhspandemicinfluenzapla... Accessed December 2012.
    1. Schanzer DL, Zheng H, Gilmore J. Statistical estimates of absenteeism attributable to seasonal and pandemic influenza from the Canadian Labour Force Survey. BMC Infect Dis. 2011;11:90. - PMC - PubMed
    1. Woods JM, Bethell RC, Coates JA, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother. 1993;37:1473–9. - PMC - PubMed
    1. GlaxoSmithKline. Prescribing information for zanamivir. 2011. http://us.gsk.com/products/assets/us_relenza.pdf/ Accessed February 2013.
    1. Genentech. US Food and Drug Administration. Prescribing information for oseltamivir. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021087s056_0212... . Accessed May 2013.

Publication types

MeSH terms

Associated data

  NODES
admin 5
INTERN 1
twitter 2